Stock futures are steady after U.S. attacks Venezuela, captures Nicolas Maduro: Live updates

Stock futures are steady after U.S. attacks Venezuela, captures Nicolas Maduro: Live updates


Traders work on the floor of the New York Stock Exchange on the first day of trading for the year on Jan. 2, 2026 in New York City.

Spencer Platt | Getty Images

Stock futures were steady on Sunday night, as global markets reacted to the U.S.’ attack on Venezuela and capture of leader Nicolas Maduro.

Dow Jones Industrial Average futures traded 7points higher. S&P 500 futures rose 0.1%, and Nasdaq-100 futures advanced 0.3%.

Following the attack, Maduro and his wife, Cilia Flores, were flown to New York — where they were charged with narco-terrorism conspiracy and other crimes. Drug trafficking, according to the indictment, “has enriched and entrenched Venezuela’s political and military elite.”

Maduro’s ouster comes more than a decade after he came to power, succeeding longtime dictator Hugo Chavez in April 2013. It also raises questions about what’s next for the country with the largest proven oil reserves in the world.

President Donald Trump said Saturday in a news conference that the U.S. would “run” Venezuela “until such time as we can do a safe, proper and judicious transition.” Secretary of State Marco Rubio appeared to walk back those remarks on Sunday, however, noting the U.S. would use leverage to meet policy goals. He also did not say the U.S. would govern Venezuela directly.

To be sure, some on Wall Street think the impact on markets from the U.S. intervention will be limited. Despite Venezuela’s massive reserves, the country produces less than 1 million barrels per day. That’s less than 1% of global production.

BCA Research chief strategist Marko Papic also noted that the Venezuelan government is “stabilized” by the country’s military.

“President Trump’s assertion that the US will ‘run the country’ and that he is not afraid of ‘troops on the ground’ should be faded as signals. The US will likely negotiate with the military and the opposition in the transitional phase,” Papic wrote to clients.

Crude prices slipped in early futures trading Sunday.

Wall Street is coming off a mixed session. The S&P 500 and Dow closed higher on Friday — the first trading day of the year — while the Nasdaq ended just below the flatline.

This week, traders will look out for the release of the December jobs report on Friday. Economists polled by Dow Jones expect the economy added 54,000 jobs last month.



Source

Citi UK CEO: ‘Phenomenal’ market resilience is keeping recession risk at bay — for now
World

Citi UK CEO: ‘Phenomenal’ market resilience is keeping recession risk at bay — for now

Tiina Lee, the CEO of Citi U.K., expects global growth to remain resilient this year, telling CNBC that a “recessionary environment” is “not our base case.” Markets have continued to perform in an orderly way, despite the economic and geopolitical upheaval caused by the Iran conflict, which entered its 60th day on Tuesday, Lee said. […]

Read More
‘Draconian development’ in Meta-Manus deal draws the line in China’s AI race with the U.S.
World

‘Draconian development’ in Meta-Manus deal draws the line in China’s AI race with the U.S.

Manus was hailed by Chinese state media as the “next DeepSeek” soon after its launch in March 2025, months before the startup relocated to Singapore. Cheng Xin | Getty Images News | Getty Images BEIJING — China’s decision to block U.S. tech giant Meta‘s $2 billion acquisition of artificial intelligence startup Manus is being seen […]

Read More
Novartis CEO warns reality of Trump’s drug pricing policy will set in over ‘the next 18 months’
World

Novartis CEO warns reality of Trump’s drug pricing policy will set in over ‘the next 18 months’

Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients. “The longer-term implications are significant,” CEO Vas Narasimhan told CNBC’s Carolin Roth. Novartis is focused on getting European and Japanese governments to quickly change […]

Read More